This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nanosys Continues Its Private Affair

Nanosys is working on a lot of potential applications that could find demand once they reach the market: fuel cells for laptops, memory for MP3 players, low-cost solar cells, etc. One of the company's founders, Larry Bock, has a stellar track record of investing in or founding biotech startups such as Ariad Pharmaceuticals, Athena Neurosciences and Neurocrine Biosciences.

"Many of the initial investors got sucked into this as a result of Larry Bock's success in the biotech world and believed that this could be replicated in nanotech," says Harper. "So four years in, they are being asked to pony up again in order to keep the company afloat long enough for them to hit pay dirt somewhere"

Charles Harris, CEO of venture firm Harris and Harris (TINY), which has participated in multiple rounds of private funding for Nanosys, says the nanotech issue is beside the point. First off, investors still labor under the misperception that nanotech is an industry rather than a field of innovation that will affect many industries. Also, Wall Street has been lukewarm toward venture-backed IPOs of all types in the past few years.

"When the Nanosys IPO was pulled, people attributed it to nanotech per se," says Harris, who adds he saw a silver lining in having Nanosys remain private. "It gave us an opportunity to put more money into the company."

What Nanosys' latest round of funding, with a broader array of private funds involved, suggests is that nanotech investment appears to be slowly attracting the interest of private investors. Whether you put the blame on Wall Street or Nanosys, the public markets remain lukewarm to nanotech.

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
NANX $0.46 0.00%
ALTR $47.37 0.00%
IRBT $32.13 0.00%
AAPL $132.54 0.00%
FB $80.54 0.00%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs